ArticleJournal of natural medicines2018
Morin protects glucocorticoid-induced osteoporosis through regulating the mitogen-activated protein kinase signaling pathway.
Article in Journal of natural medicines, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 17 citations in OpenAlex.
- Morin: a promising hepatoprotective agent against drug and chemical-induced liver injury.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Enhancing bone regeneration using kaempferol as an osteoprotective compound: signaling mechanisms, delivery strategies, and potential applications.Journal of biological engineering · 2025Review
- Morin Improves the Bone Histomorphology and Biochemical Markers in an Animal Model of Ovariectomy-Induced Osteoporosis by Suppressing Autophagy and Apoptosis.Food science & nutrition · 2024Article
- Natural Morin-Based Metal Organic Framework Nanoenzymes Modulate Articular Cavity Microenvironment to Alleviate Osteoarthritis.Research (Washington, D.C.) · 2023Article
- Morin Disrupts Cytoskeleton Reorganization in Osteoclasts through an ROS/SHP1/c-Src Axis and Grants Protection from LPS-Induced Bone Loss.Antioxidants (Basel, Switzerland) · 2022Article
- Supplementation of Morin Restores the Altered Bone Histomorphometry in Hyperglycemic Rodents via Regulation of Insulin/IGF-1 Signaling.Nutrients · 2021Article
- Kaempferol Ameliorates the Inhibitory Activity of Dexamethasone in the Osteogenesis of MC3T3-E1 Cells by JNK and p38-MAPK Pathways.Frontiers in pharmacology · 2021Article
- Combination Therapy of Wuweizi (BioMed research international · 2020Article
- Beneficial effects of Cuscuta chinensis extract on glucocorticoid-induced osteoporosis through modulation of RANKL/OPG signals.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Our aim is to investigate the potential therapeutic value of morin against osteoporosis and elucidate the mechanism of action. Osteoporosis was induced in rats by a subcutaneous injection of dexamethasone (DEX) for 5 weeks. Body weight was regularly monitored. Body mineral density (BMD) was determined at proximal femurs using dual energy X-ray absorptiometry. Pathological examination was performed by hematoxylin and eosin staining. The relative expression of osteogenic and bone resorption markers was determined by real-time polymerase chain reaction and Western blotting, respectively. Activation of the MAPK signaling pathway was analyzed by Western blotting. Body weight and BMD were both significantly decreased in osteoporotic rats, although BMD was partially restored by intraperitoneal morin administration. Morin treatment also increased the number of trabecular bones in DEX-induced rats. Mechanistically, morin reversed the decrease of osteogenic markers and increase of bone resorption markers, which might eventually be mediated by modulation of MAPK signaling cascades. Here, we uncovered the therapeutic effect of morin against osteoporosis and demonstrated its suppressive action on the MAPK pathway in this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.